Preclinical studies reveal oxytocin's potential to reduce obesity by modulating food intake and metabolism, suggesting new treatment avenues.
Oxytocin (OXT) and its neuronal system demonstrate significant therapeutic potential for obesity and related metabolic disorders. Preclinical studies indicate that OXT promotes weight loss by suppressing food intake, enhancing energy expenditure, and stimulating lipolysis. However, clinical trial results have been heterogeneous, and challenges such as long-term safety concerns and difficulties in dose control hinder its clinical translation. Further elucidation of the neuroendocrine interactions between oxytocinergic neurons and metabolic regulation, along with exploration of targeted neuronal activity modulation, may provide critical breakthroughs for developing effective and safe obesity treatments.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: